You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Compared with RT-PCR testing, Abbott's BinaxNow test had a sensitivity of 64 percent for samples from symptomatic people and nearly 36 percent for asymptomatic people.
SureScreen's test will be deployed in educational settings, as well as for the testing of National Health Service and care home staff.
The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.
The firm sells a rapid, point-of-care, PCR platform for infectious disease diagnostics, including SARS-CoV-2, influenza, respiratory syncytial virus, and strep A.
The company said it had signed definitive agreements to sell $6.6 million of its American Depository Shares to undisclosed institutional investors.
The company's two largest investors will purchase $25 million of its common shares, with proceeds supporting ongoing test commercialization.
The companies will combine Hamilton's LabElite DeCapper with the Rhinostic swab collection device for hands-free, high-throughput sample processing.